An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients With Moderate to Severe Asthma (EXCELS)

Trial Profile

An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients With Moderate to Severe Asthma (EXCELS)

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 May 2017

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Asthma
  • Focus Adverse reactions
  • Acronyms EXCELS
  • Sponsors Genentech
  • Most Recent Events

    • 14 Sep 2016 Results assessing association between omalizumab and cardiovascular and cerebrovascular events in EXCELS, published in the Journal of Allergy and Clinical Immunology.
    • 12 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top